Regulation of the Proliferation and Survival of Normal and Neoplastic Human Mast Cells
This protocol is designed to examine those growth potentiating and inhibiting factors which
regulate mast cell number and survival in patients with mastocytosis, and to explore the
molecular basis of the disease process in hopes of improving therapy. Patients will carry
the diagnosis of mastocytosis based on abnormal bone marrow biopsy and aspirate, abnormal
skin biopsy, presence of urticaria pigmentosa, and if available, elevated serum tryptase
level greater than 20 ng/ml and the presence of aberrant mast cell morphology and surface
markers of CD2 and CD25. Medical work-up is in accordance with standard medical practice.
Mastocytosis patients will be children and adults from birth to 80 years of age. The
protocol is designated for up to a 1-year enrollment period; with only a small number of
enrolled patients that will stay on study for more than one visit, based on investigator
assessment of contribution to study objectives. Patients may be asked to re-enter this
protocol at a later time for further research or entry into protocol 98-I-0027. This is not
a therapeutic protocol and does not involve infusion of any manipulated cells, viruses or
DNA constructs into human subjects.
Dean D Metcalfe, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
United States: Federal Government
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Bethesda, Maryland 20892|